Compounds > sorafenib
Page last updated: 2024-09-05

sorafenib and Atrophy

sorafenib has been researched along with Atrophy in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Busaidy, NL; Habra, MA; Schellingerhout, D; Shawa, H1
Goldwasser, F; Hescot, S; Vignaux, O1
Bruckner, T; Ganten, MK; Ganten, TM; Koschny, R; Schuessler, M1
Chen, MS; Li, SP; Pawlik, TM; Spolverato, G; Xu, L; Zhang, YJ; Zhao, J; Zhou, DS1
Eskens, FA; Mathijssen, RH; Peeters, RP; van der Lugt, A; van Doorn, L; Visser, TJ1

Other Studies

5 other study(ies) available for sorafenib and Atrophy

ArticleYear
Unilateral renal artery stenosis with renal atrophy in a patient with metastatic papillary thyroid carcinoma treated with sorafenib.
    BMJ case reports, 2013, May-15, Volume: 2013

    Topics: Antineoplastic Agents; Atrophy; Carcinoma; Carcinoma, Papillary; Female; Humans; Kidney; Middle Aged; Niacinamide; Phenylurea Compounds; Renal Artery Obstruction; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms

2013
Pancreatic atrophy--a new late toxic effect of sorafenib.
    The New England journal of medicine, 2013, Oct-10, Volume: 369, Issue:15

    Topics: Atrophy; Diarrhea; Humans; Niacinamide; Pancreas; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Sorafenib

2013
Pancreatic Atrophy in Hepatocellular Carcinoma Patients Receiving Long-Term Treatment with Sorafenib.
    Oncology, 2015, Volume: 89, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Atrophy; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Pancreas; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome

2015
Long-term therapy with sorafenib is associated with pancreatic atrophy.
    The Journal of surgical research, 2015, Volume: 199, Issue:2

    Topics: Aged; Antineoplastic Agents; Atrophy; Carcinoma, Hepatocellular; China; Cohort Studies; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Pancreas; Pancreatic Diseases; Phenylurea Compounds; Sorafenib; Treatment Outcome

2015
Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma.
    Thyroid : official journal of the American Thyroid Association, 2011, Volume: 21, Issue:2

    Topics: Aged; Antineoplastic Agents; Atrophy; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Thyroid Gland; Thyroiditis; Ultrasonography

2011